Belladonna Alkaloids Market
Number of pages: 100 | Report Format: PDF | Published date: May 26, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023 to 2031
|
Report Attribute |
Details |
|
CAGR |
6.85% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Type, Application, Route of Administration, End User, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the belladonna alkaloids market is expected to register a revenue CAGR of 6.85% during the forecast period 2023-2031
Belladonna Alkaloids Market Fundamentals
Belladonna alkaloids are a group of naturally occurring compounds derived from various plants, primarily the belladonna plant (Atropa belladonna), also known as the deadly nightshade. The major belladonna alkaloids include atropine, hyoscyamine, and scopolamine. These alkaloids possess anticholinergic properties, meaning they block the effects of the neurotransmitter acetylcholine in the body. Belladonna alkaloids have a long history of medicinal use and have various applications in the pharmaceutical industry. Atropine, for example, is used to dilate pupils, treat bradycardia (slow heart rate), and manage certain gastrointestinal disorders. Hyoscyamine is employed for its antispasmodic effects in conditions like irritable bowel syndrome. Scopolamine is commonly used for motion sickness prevention and as a preoperative medication. The demand for belladonna alkaloids is expanding in emerging economies, particularly in the Asia Pacific and Latin American regions. Factors such as increasing healthcare expenditure, growing population, rising prevalence of chronic diseases, and improving healthcare infrastructure contribute to the market growth in these regions.
Belladonna Alkaloids Market Dynamics
The global belladonna alkaloids market has witnessed several trends in recent years. With the global population aging, there is an increasing incidence of age-related health issues, including conditions that may be treated with belladonna alkaloids. The elderly often require medications targeting specific symptoms or conditions related to urinary incontinence, gastrointestinal disorders, or eye-related problems. Urinary incontinence is a very common disorder among older adults, it is estimated that between 15% and 35% of community-dwelling adults in the United States aged 60 or over suffer from urinary incontinence. The growing prevalence of medical conditions such as gastrointestinal disorders, respiratory diseases, ophthalmic conditions, and urinary incontinence drives the demand for anticholinergic medications, including those containing belladonna alkaloids. Developments improve the convenience and efficiency of belladonna alkaloid treatments in drug delivery systems, such as transdermal patches, extended-release formulations, and improved ocular delivery techniques. By increasing patient compliance and broadening the variety of available treatments, these advancements help the global belladonna market to thrive. Natural and plant-based treatments, including herbal and alternative medicine, are popular worldwide. The market for formulations containing belladonna alkaloids is being driven by the growing recognition and acceptance of belladonna alkaloids, sourced from natural sources, as a component of herbal remedies. The pharmaceutical business, including the market for belladonna alkaloids, is expanding thanks to rising healthcare costs, particularly in emerging economies. The market is growing as a result of higher investments in healthcare infrastructure, improved access to healthcare services, and cutting-edge treatment choices.
However, the global belladonna alkaloids market growth is set to be challenged by several unfavorable factors. Rising cases of fatal side effects and inconsistencies among patients is one of the major restraining factors.
Belladonna Alkaloids Market Ecosystem
The global belladonna alkaloids market is analyzed from the following perspectives: type, application, route of administration, end user, and region.
Belladonna Alkaloids Market by Type
Based on the type, the belladonna alkaloids market is segmented into atropine, hyoscyamine, and scopolamine.
Atropine accounts for the highest revenue share with a 7.5% growth rate in the global belladonna alkaloids market. Atropine is a widely used belladonna alkaloid with a broad range of medical applications. It is commonly employed for its anticholinergic effects, including pupil dilation, relaxation of smooth muscles, and decreased secretions. Atropine is used in various clinical settings, such as ophthalmology for dilating the pupil during eye examinations or surgeries, cardiology for treating bradycardia (slow heart rate), and as a preoperative medication to reduce secretions. Additionally, it is a more potent alkaloid and is long-acting.
The hyoscyamine segment is projected to record a high revenue CAGR in the forecast period. Hyoscyamine is also a belladonna alkaloid that possesses anticholinergic properties. It is primarily used for its antispasmodic effects on smooth muscles, effectively treating gastrointestinal conditions such as irritable bowel syndrome (IBS) and functional dyspepsia. Hyoscyamine helps to relieve abdominal pain, cramping, and other symptoms associated with these disorders.
Belladonna Alkaloids Market by Application
Based on the application, the global belladonna alkaloids market is segmented into gastrointestinal disorders, respiratory disorders, overactive bladder, preoperative settings, and others.
The gastrointestinal segment is projected to grow at a high revenue CAGR during the forecast period. Atropine treats gastrointestinal conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and irritable bowel syndrome (IBS). It lessens digestive secretions and motility, easing symptoms brought on by these illnesses.
Ophthalmology is the other segment that is projected to record a high revenue CAGR in the global belladonna alkaloids market. A report from the WHO estimates that 2.2 billion people worldwide will have some form of vision impairment or be blinded as a result of eye diseases like refractive errors, cataracts, glaucoma, AMD, and diabetic retinopathy in 2020, with 1 billion of those people having a condition that could have been avoided or treated. Among the conditions it is used to treat are uveitis, amblyopia, and cycloplegia. Prior to surgery, anaesthesia with atropine is also delivered to enlarge the pupil and halt intraoperative miosis. The others section has applications for bradycardia, poison ivy, and other ailments.
Belladonna Alkaloids Market by Route of Administration
Based on the route of administration, the global belladonna alkaloids market is segmented into oral, topical, injectable, and others.
The injectable segment accounts for the highest revenue share in the global belladonna alkaloids market. Some types of nerve agents and chemical weapon poisoning are treated using injectable alkaloids. It functions by inhibiting the body's production of acetylcholine, which is essential for nerve impulse transmission. To treat bradycardia (slow heart rate), tachycardia (rapid heart rate), and other irregular cardiac rhythms, injectable atropine is utilized.
Belladonna Alkaloids Market by End User
Based on the end user, the global belladonna alkaloids market is segmented into hospitals, pharmaceutical companies, research institutions and laboratories, and others.
The hospital segment accounts for the largest revenue share in the global belladonna alkaloids market. The growth of this market segment is being driven by both the ease with which hospital can be found and the rising number of hospital patients. According to estimates, the market growth will be fueled by the increasing number of patients admitted to hospitals with stomach and gastrointestinal problems like diverticulitis, irritable bowel syndrome, and spastic muscular states. The major factor driving the growth is the rising prevalence of irritable bowel syndrome (IBS). According to the Lancet, IBS affects between 25 and 45 million people in the United States. IBS affects between 25 and 45 million people in the United States.
Belladonna Alkaloids Market by Region
Geographically, the global belladonna alkaloids market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounts for the largest revenue share in the global belladonna alkaloids market. The main drivers of this market growth are the US and Canada. Some of the major reasons propelling the growth of this market in North America include the rising elderly population and the prevalence of gastrointestinal illnesses. According to the American College of Gastroenterology (ACG), over 60% of Americans will eventually develop GERD. People's shifting dietary patterns and lifestyles, which impact their digestive and gastric systems, are predicted to drive market segment growth.
The Asia Pacific region is projected to experience the highest CAGR during the forecast period in the global belladonna alkaloids market. Due to rising product demand for numerous applications, including gastrointestinal problems, other uses, and ophthalmology, the area is also expected to expand considerably. Additionally, the presence of cutting-edge healthcare facilities and the rising number of clinical studies being undertaken in this area is anticipated to support the growth of the market.
Latin America as a result of elements including rising gastrointestinal disorder prevalence and public health awareness of the illness. The belladonna alkaloids market is anticipated to increase in this region as a result of rising healthcare costs and government initiatives.
Belladonna Alkaloids Market Competitive Landscape
The prominent players operating in the global belladonna alkaloids market are: -
Belladonna Alkaloids Market Strategic Developments
Belladonna alkaloids belong to a class of drugs known as anticholinergics/antispasmodics. Belladonna alkaloids help to reduce the symptoms of stomach and intestinal cramping. They work by slowing the natural movements of the gut and by relaxing the muscles in the stomach and intestines.
The revenue CAGR for the belladonna alkaloids market is 6.85% during the forecast period.
Pfizer Inc., Caleb Pharmaceuticals, Inc., Baxter International Inc., C2 Pharma, and Myungmoon Pharm Co., Ltd are a few of the major players in the belladonna alkaloids market.
Asia Pacific is the region with the highest growth rate in the global belladonna alkaloids market.
The fatal side effects and strict government regulations restrict the growth of the global belladonna alkaloids market.
*Insights on financial performance are subject to the availability of information in the public domain